The crisis of no new antibiotics--what is the way forward?
- PMID: 22101066
- DOI: 10.1016/S1473-3099(11)70316-4
The crisis of no new antibiotics--what is the way forward?
Abstract
Antibiotic use not only underpins modern medicine, but has brought huge changes to the world, especially in expectations of survival of children into adulthood. The theme of World Health Day, 2011, was "antimicrobial resistance: no action today and no cure tomorrow". The demise of antibacterial drug discovery brings the spectre of untreatable infections. To prevent this crisis immediate action is needed and a new initiative, Antibiotic Action, has been launched. By bringing together communities who need these drugs with academia, health-care professionals, and pharmaceutical companies, this initiative aims to strengthen and enhance academic-industrial partnerships, bring about revision of costly and laborious processes of licensing and regulation of new antibiotics, and address the economics of antimicrobial drugs (cost of use vs profit). A global alliance for antibiotic drug discovery and development would provide a platform for these initiatives.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
The global need for effective antibiotics-moving towards concerted action.Drug Resist Updat. 2011 Apr;14(2):68-9. doi: 10.1016/j.drup.2011.02.006. Epub 2011 Apr 1. Drug Resist Updat. 2011. PMID: 21444235 Review.
-
Antibiotic research and development: business as usual?J Antimicrob Chemother. 2015;70(6):1604-7. doi: 10.1093/jac/dkv020. Epub 2015 Feb 10. J Antimicrob Chemother. 2015. PMID: 25673635
-
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.J Antimicrob Chemother. 2016 Feb;71(2):290-5. doi: 10.1093/jac/dkv339. Epub 2015 Nov 15. J Antimicrob Chemother. 2016. PMID: 26568581 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.J Antimicrob Chemother. 2011 Sep;66(9):1948-53. doi: 10.1093/jac/dkr260. Epub 2011 Jun 23. J Antimicrob Chemother. 2011. PMID: 21700625
Cited by
-
Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics.Front Microbiol. 2016 Aug 3;7:1209. doi: 10.3389/fmicb.2016.01209. eCollection 2016. Front Microbiol. 2016. PMID: 27536293 Free PMC article. Review.
-
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.Antimicrob Resist Infect Control. 2012 Feb 14;1(1):11. doi: 10.1186/2047-2994-1-11. Antimicrob Resist Infect Control. 2012. PMID: 22958833 Free PMC article.
-
Going viral: next-generation sequencing applied to phage populations in the human gut.Nat Rev Microbiol. 2012 Sep;10(9):607-17. doi: 10.1038/nrmicro2853. Epub 2012 Aug 6. Nat Rev Microbiol. 2012. PMID: 22864264 Free PMC article. Review.
-
In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.Antimicrob Agents Chemother. 2016 Nov 21;60(12):7134-7145. doi: 10.1128/AAC.00453-16. Print 2016 Dec. Antimicrob Agents Chemother. 2016. PMID: 27645240 Free PMC article.
-
In Vitro and In Vivo Antimicrobial Activity of Hypochlorous Acid against Drug-Resistant and Biofilm-Producing Strains.Microbiol Spectr. 2022 Oct 26;10(5):e0236522. doi: 10.1128/spectrum.02365-22. Epub 2022 Oct 3. Microbiol Spectr. 2022. PMID: 36190404 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical